UBC Videos
-
A Multi-Disciplinary Perspective On Decentralized Study Design
7/1/2021
The biopharmaceutical industry is rapidly adopting methodologies that decentralize research by harnessing transformative data acquisition and patient engagement thus taking the research beyond the walls of the legacy study setting. To truly realize the promise of decentralized research models, a dynamic array of technological capabilities, traditional research core competencies, and innovative study design expertise is required. Join us as we explore operational challenges, technical solutions, and design considerations.
-
Global, Industry-Leading Decentralized Clinical Research Offering
5/6/2021
This video explains how a fully integrated solution is driving the trend towards decentralized clinical trial (DCT) designs and tactics to support phase II-IV clinical trials, pragmatic studies, and late-stage observational research.
-
Unlocking The Evidence-Generation Potential Of The EMR
7/10/2020
We have only just begun to scratch the surface of the potential of the electronic medical record (EMR) to support research and evidence generation in the realm of drug development. During this discussion, we examine several practical applications of real word data from EMRs to support research.
-
What You Need To Know About Assembling An Integrated Registry
7/10/2020
Learn how to overcome the challenges of combining multiple registries to generate richer data in order to better understand disease progression and real world practice patterns.
-
The Value Of RWD In Safety Signal Refinement
5/24/2019
Population-based RWD are increasingly used by US and EU regulators to complement passive safety surveillance that is based on review of adverse event spontaneous reports. The presentation focuses on a recommended analytic approach for safety scientists, epidemiologists, and other researchers for evaluating the causality of a signal identified from one or more data sources.
-
Virtual Study Designs
5/14/2019
Virtual study designs are transforming the way biopharmaceutical businesses conduct research. Tactics that decentralize the approach to clinical and observational research are ushering in a new paradigm of efficient data collection and patient centric engagement.
-
Risk Evaluation And Mitigation Strategy (REMS) Overview
4/29/2019
UBC’s Natalie O’Donnell, Executive Director, SERRM, provides a Risk Evaluation and Mitigation Strategy (REMS) overview. Learn more about the importance in partnering with an experienced REMS team for your next study.
-
Interventional vs. Observational Studies
4/15/2019
Dr. Annette Stemhagen, SVP & Chief Scientific Officer, speaks to the differences between Interventional and Observational Studies.
-
Pregnancy Exposure Registry
4/15/2019
Dr. Annette Stemhagen, SVP & Chief Scientific Officer, speaks to Pregnancy Exposure Registries (PERs) and why partnering with an experienced team is so vital.